Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis

被引：15

作者：

Malkonen, Tarja ^{[1
]}

Nuutinen, Pauliina ^{[1
]}

Hallinen, Taru ^{[2
]}

Soini, Erkki ^{[2
]}

Nissinen, Riikka ^{[3
]}

Wennerstom, Christina ^{[4
]}

Rantanen, Tapio ^{[5
]}

Hagman, Johanna H. ^{[6
,7
]}

Harvima, Rauno ^{[8
,9
]}

Hook-Nikanne, Johanna ^{[10
]}

Ilves, Tiina ^{[11
]}

Lintu, Paivi ^{[7
]}

Malanin, Ken ^{[12
]}

Soramaki, Iina ^{[13
]}

Tasanen, Kaisa ^{[14
,15
,16
]}

Teho, Arja ^{[17
]}

Vahavihu, Katja ^{[18
]}

Italinna, Sari ^{[19
]}

Leinonen, Pekka ^{[20
]}

Sarajarvi, Piia ^{[21
]}

Huilaja, Laura ^{[14
,15
,16
]}

Pasternack, Rafael ^{[22
,23
]}

机构：

[1] Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland

[2] ESiOR Oy, Kuopio, Finland

[3] Janssen Cilag Oy, Espoo, Finland

[4] Janssen Cilag, Solna, Sweden

[5] Infoderm Oy, Tampere, Finland

[6] Vaasa Cent Hosp, Vaasa, Finland

[7] Turku Univ Hosp, Dept Dermatol, Turku, Finland

[8] Kuopio Univ Hosp, Dept Dermatol, Kuopio, Finland

[9] Univ Eastern Finland, Kuopio, Finland

[10] HUS Helsinki Univ Hosp, Lohja Hosp, Lohja, Finland

[11] Mikkeli Cent Hosp, Dept Dermatol, Mikkeli, Finland

[12] Alands Cent Hosp, Dept Dermatol & Allergol, Maarianhamina, Finland

[13] Keski Suomi Cent Hosp, Dept Dermatol, Jyvaskyla, Finland

[14] Univ Oulu, PEDEGO Res Unit, Oulu, Finland

[15] Oulu Univ Hosp, Dept Dermatol, Oulu, Finland

[16] Oulu Univ Hosp, Med Res Ctr, Oulu, Finland

[17] Savonlinna Cent Hosp, Dept Dermatol, Savonlinna, Finland

[18] Kanta Hame Cent Hosp, Dept Dermatol & Allergol, Hameenlinna, Finland

[19] Paijat Hame Cent Hosp, Dept Dermatol, Lahti, Finland

[20] Kainuu Cent Hosp, Dept Dermatol & Venereol, Kajaani, Finland

[21] Mehilainen Lansi Pohja, Dept Dermatol, Kemi, Finland

[22] Tampere Univ Hosp, Dept Dermatol, Tampere, Finland

[23] Tampere Univ, Tampere, Finland

来源：

ACTA DERMATO-VENEREOLOGICA | 2022年 / 102卷

关键词：

psoriasis; guselkumab; treatment outcome; real-world; persistence;

D O I：

10.2340/actadv.v101.910

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Guselkumab treatment outcomes and persistence were assessed in a real-world cohort of Finnish patients with difficult-to-treat plaque psoriasis over a median follow-up of 1 year. Data on 181 patients who initiated guselkumab at the 15 study centres were collected retrospectively from the patient charts. Prior exposure to biologic therapies was common, with 56% and 35% having used at least 1 and 2 biologics, respectively. Median guselkumab treatment duration was 11 months with 21 patients (12%) discontinuing treatment during follow-up. Of 85 patients with a follow-up duration of at least 1 year, 73 (86%) were still on guselkumab at 1 year. Significant improvements during follow-up were seen in the absolute Psoriasis Area and Severity Index (PASI) scores with 32 patients (80%) having absolute PASI <= 2 after a 9-14-month treatment. Guselkumab treatment was effective and treatment persistence was high in the nationwide Finnish real-life setting.

引用

页数：5

共 50 条

[1] TREATMENT SATISFACTION OF GUSELKUMAB FOR PLAQUE PSORIASIS PATIENTS IN A MULTI-NATIONAL, REAL-WORLD SETTING
Molaei, M.
Yang, F.
Fitzgerald, T.
Piercy, J.
Lucas, J.
Teneralli, R.
[J]. VALUE IN HEALTH, 2022, 25 (12) : S479 - S479
[2] Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
Van Muijen, Marloes E.
Thomas, Sarah E.
Vellinga, Douwe
Bouwman, Silke
Van Doorn, Martijn B. A.
Politiek, Klaziena
Otero, Marisol E.
Van den Reek, Juul M. P. A.
De Jong, Elke M. G. J.
[J]. ACTA DERMATO-VENEREOLOGICA, 2022, 102
[3] Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year
Galluzzo, Marco
Talamonti, Marina
Bernardini, Nicoletta
Chiricozzi, Andrea
De Simone, Clara
Bonifati, Claudio
Bruni, Pierluigi
Diotallevi, Federico
Esposito, Maria
Graceffa, Dario
Hansel, Katharina
Loconsole, Francesco
Moretta, Gaia
Mugheddu, Cristina
Papini, Manuela
Richetta, Antonio
Skroza, Nevena
Atzori, Laura
Fargnoli, Maria Concetta
Persechino, Severino
Offidani, Annamaria
Stingeni, Luca
Peris, Ketty
Potenza, Concetta
Bianchi, Luca
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (12) : 1585 - 1592
[4] Persistence and effectiveness of guselkumab treatment in patients with moderate-to-severe plaque psoriasis in a non-interventional real-world setting: The SPRING study
Puig, L.
Dauden, E.
Cuervas-Mons, M.
Novella, C.
Guisado, C.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023,
[5] Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab
Cazana, Tamara Gracia
Monroig, Josep Riera
Izu, Rosa
Yanguas, Ignacio
Espes, Marta Lorda
Salas, Maria Pilar Sanchez
Gil, Miguel Fernando Garcia
Bielsa, Alba Navarro
Manrique, Beatriz Aldea
Blasco, Manuel Almenara
de Aranibar, Francisco Javier Garcia-Latasa
Fuentelsaz, Victoria
Callaghan, Ana Morales
Ara-Martin, Mariano
[J]. JAAD INTERNATIONAL, 2024, 16 : 66 - 71
[6] Persistence, effectiveness, and real-world outcomes in psoriasis patients treated with secukinumab in Portugal
Mendes-Bastos, Pedro
Morais, Paulo
Ferreira, Paulo
Loureiro, Manuela
Sanganha, Joaquina
Santiago, Luis
Basto, Antonio Sousa
Henrique, Martinha
[J]. DERMATOLOGIC THERAPY, 2022, 35 (07)
[7] CHARACTERISTICS OF PLAQUE PSORIASIS PATIENTS INITIATING GUSELKUMAB BY COUNTRY: A MULTI-NATIONAL, REAL-WORLD SURVEY OF DERMATOLOGY PRACTICES
Molaei, M.
Yang, F.
Fitzgerald, T.
Piercy, J.
Lucas, J.
Teneralli, R.
[J]. VALUE IN HEALTH, 2022, 25 (12) : S478 - S479
[8] Real-world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis
Iznardo, H.
Vilarrasa, E.
Lopez-Ferrer, A.
Puig, L.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : 660 - 662
[9] Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
April W. Armstrong
Timothy Fitzgerald
Robert R. McLean
Amanda Teeple
Jonathan P. Uy
Mobolaji Olurinde
Katelyn Rowland
Lin Guo
Ying Shan
Kristina Callis Duffin
[J]. Dermatology and Therapy, 2023, 13 : 629 - 640
[10] One-year real-world effectiveness of guselkumab in patients with moderate-to-severe plaque psoriasis: analysis from the BADBIR
Savage, Laura
Wang, Xiayi
Johnson, David
Gillespie, Justin
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 76 - 76

← 1 2 3 4 5 →